Abstract
Multiple combinations of antiretroviral drugs have remarkably improved the treatment of HIV-1 infection. However, life-long treatments and drug resistance are still an open issue that requires continuous efforts for the identification of novel antiviral drugs.
Background: The reverse transcriptase-associated ribonuclease H (RNase H) hydrolyzes the HIV genome to allow synthesizing viral DNA. Currently, no RNase H inhibitors (RHIs) have reached the clinical phase. Therefore, RNase H can be defined as an attractive target for drug design.
Objective: Despite the wealth of information available for RNase H domain, the development of RHIs with high specificity and low cellular toxicity has been disappointing. However, it is now becoming increasingly evident that reverse transcriptase is a highly versatile enzyme, undergoing major structural alterations to complete its catalysis, and that exists a close spatial and temporal interplay between reverse transcriptase polymerase and RNase H domains. This review sums up the present challenges in targeting RNase H encompassing the challenges in selectively inhibiting RNase H vs polymerase and/or HIV-1 integrase and the weak antiviral activity of active site inhibitors, probably for a substrate barrier that impedes small molecules to reach the targeted site. Moreover, the focus is given on the most recent progress in the field of medicinal chemistry that has led to the identification of several small molecules as RHIs in the last few years.
Conclusion: RHIs could be a new class of drugs with a novel mechanism of action highly precious for the treatment of resistant HIV strains.
Keywords: Ribonuclease H, reverse transcriptase, metalloenzyme, RNase H inhibitors, drug design, HIV-1, AIDS, antiviral.
Current Medicinal Chemistry
Title:Small-molecule Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Function: Challenges and Recent Developments
Volume: 28 Issue: 30
Author(s): Valentina Noemi Madia, Antonella Messore, Alessandro De Leo, Valeria Tudino, Ivano Pindinello, Francesco Saccoliti, Daniela De Vita, Luigi Scipione, Roberta Costi*Roberto Di Santo
Affiliation:
- Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur - Fondazione Cenci Bolognetti, “Sapienza” Università di Roma, p.le Aldo Moro 5, I-00185 Rome,Italy
Keywords: Ribonuclease H, reverse transcriptase, metalloenzyme, RNase H inhibitors, drug design, HIV-1, AIDS, antiviral.
Abstract:
Multiple combinations of antiretroviral drugs have remarkably improved the treatment of HIV-1 infection. However, life-long treatments and drug resistance are still an open issue that requires continuous efforts for the identification of novel antiviral drugs.
Background: The reverse transcriptase-associated ribonuclease H (RNase H) hydrolyzes the HIV genome to allow synthesizing viral DNA. Currently, no RNase H inhibitors (RHIs) have reached the clinical phase. Therefore, RNase H can be defined as an attractive target for drug design.
Objective: Despite the wealth of information available for RNase H domain, the development of RHIs with high specificity and low cellular toxicity has been disappointing. However, it is now becoming increasingly evident that reverse transcriptase is a highly versatile enzyme, undergoing major structural alterations to complete its catalysis, and that exists a close spatial and temporal interplay between reverse transcriptase polymerase and RNase H domains. This review sums up the present challenges in targeting RNase H encompassing the challenges in selectively inhibiting RNase H vs polymerase and/or HIV-1 integrase and the weak antiviral activity of active site inhibitors, probably for a substrate barrier that impedes small molecules to reach the targeted site. Moreover, the focus is given on the most recent progress in the field of medicinal chemistry that has led to the identification of several small molecules as RHIs in the last few years.
Conclusion: RHIs could be a new class of drugs with a novel mechanism of action highly precious for the treatment of resistant HIV strains.
Export Options
About this article
Cite this article as:
Madia Noemi Valentina , Messore Antonella , De Leo Alessandro , Tudino Valeria , Pindinello Ivano , Saccoliti Francesco , De Vita Daniela , Scipione Luigi , Costi Roberta *, Di Santo Roberto, Small-molecule Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Function: Challenges and Recent Developments, Current Medicinal Chemistry 2021; 28 (30) . https://dx.doi.org/10.2174/0929867328666210322164557
DOI https://dx.doi.org/10.2174/0929867328666210322164557 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development, Recent Achievements and Current Directions of Research into GABA Uptake Inhibitors
Current Medicinal Chemistry Insight on Structural Modification, Cytotoxic or Anti-Proliferative Activity, Structure-Activity Relationship of Berberine Derivatives
Medicinal Chemistry Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Structure Based Design of 11β-HSD1 Inhibitors
Current Pharmaceutical Biotechnology NOX-2 Inhibitors may be Potential Drug Candidates for the Management of COVID-19 Complications
Current Drug Research Reviews Current Concepts for the Combined Treatment Modality of Ionizing Radiation with Anticancer Agents
Current Pharmaceutical Design Overview of Piperine: Bioactivities, Total Synthesis, Structural Modification, and Structure-Activity Relationships
Mini-Reviews in Medicinal Chemistry Sexual Dysfunction in Men and Women with Diabetes: A Reflection of their Complications?
Current Diabetes Reviews COVID-19 and Ehlers-Danlos Syndrome: The Dangers of the Spike Protein of SARS-CoV-2
Infectious Disorders - Drug Targets Antimicrobial Potential of Natural Compounds of Zingiberaceae Plants and their Synthetic Analogues: A Scoping Review of <i>In vitro</i> and <i>In silico</i> Approaches
Current Topics in Medicinal Chemistry Recent Advances in Antiviral Activity of Benzo/Heterothiadiazine Dioxide Derivatives
Current Medicinal Chemistry An Alternative “Trojan Horse” Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology
Endocrine, Metabolic & Immune Disorders - Drug Targets Covid-19: Pathophysiology; Mechanism of Transmission and Possible Molecular Drug Target for Management
Current Molecular Pharmacology The Influence of DMPK as an Integrated Partner in Modern Drug Discovery
Current Drug Metabolism Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents
Current Pharmaceutical Design New Frontier in Antiviral Drugs for Disorders of the Respiratory System
Recent Advances in Anti-Infective Drug Discovery The Application of Trialkoxysilane as Transmetallation Reagent in Organic Synthesis
Current Organic Chemistry Identifying the Hub Proteins from Complicated Membrane Protein Network Systems
Medicinal Chemistry Electrostatics of Pharmaceutical Aerosols for Pulmonary Delivery
Current Pharmaceutical Design Target Recognition in SAR Image by Joint Classification of Target Region and Shadow
Recent Advances in Electrical & Electronic Engineering